Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy, Safety, and Pharmacokinetics of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors Baudax Bio; Societal CDMO
- 29 Oct 2014 Results published in a Recro Pharma media release.
- 04 Sep 2014 Primary endpoint has not been met. (Summed pain intensity difference over the first 48 hours (SPID48))
- 04 Sep 2014 Status changed from recruiting to discontinued, as reported in a Recro Pharma media release.